Lifestyle medicines
- 25 November 2000
- Vol. 321 (7272) , 1341-1344
- https://doi.org/10.1136/bmj.321.7272.1341
Abstract
Sildenafil and orlistat, prescribed for erectile dysfunction and obesity respectively, have been labelled as “lifestyle drugs” in the popular imagination. Although this description may trivialise serious medical conditions for which the drugs are indicated, it encapsulates concerns that some indications for these drugs might be regarded as issues of personal choice rather than illness. It is difficult to define what we mean by the term lifestyle drug since the perception of what is illness and what is within the sphere of personal responsibility rather than health care may depend on whether one is a potential patient or a potential “payer.” The perception may depend on social and cultural norms too,1 and it is also a function of how a medicine is used. For instance, most people would agree that the prescription of sildenafil for a healthy man unhappy with his sexual performance is a lifestyle use, but would consider differently the case of a diabetic man with neuropathy. A working definition for this paper might be that a lifestyle drug is one used for “non-health” problems or for problems that lie at the margins of health and wellbeing (see table). A wider definition would include drugs that are used for health problems that might be better treated by a change in lifestyle; this definition might include drugs such as lipid lowering agents or proton pump inhibitors. #### Summary points Lifestyle drugs are drugs used for non-health problems or for conditions that lie at the boundary between a health need and a lifestyle wish These drugs threaten the financial sustainability of current health systems Traditional approaches to regulating medicines are not effective for lifestyle drugs; coordinated action is needed to manage pharmaceutical policy nationally and locally Greater public involvement is essential in establishing priorities Lifestyle drugs may promote debate about appropriate directions of …Keywords
This publication has 15 references indexed in Scilit:
- Valuing the effects of sildenafil in erectile dysfunctionBMJ, 2000
- Is norethisterone a lifestyle drug? Results of database analysisBMJ, 2000
- Prescribing for Obesity1999
- UK issues guidance on prescribing ViagraBMJ, 1999
- The NHS: possibilities for the endgameBMJ, 1999
- Compliance with restrictions on the subsidized use of proton pump inhibitors in AustraliaBritish Journal of Clinical Pharmacology, 1998
- Prescription charges: change overdue?BMJ, 1998
- Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research DatabaseBMJ, 1998
- Retracing the Oregon trail: the experience of rationing and the Oregon health planBMJ, 1998
- Scenario analysis of the future of medicinesBMJ, 1994